Mayo Clinic Study Says Blood Testing Could Suffice for CML Assessment

Peripheral blood testing could provide sufficient cytogenetic information for some patients newly diagnosed with chronic myeloid leukaemia.

Retrospective Analysis of 17 Patients

Researchers at the Mayo Clinic in Rochester, Minnesota, examined whether blood samples alone provide sufficient cytogenetic data during initial diagnostic assessments.

The retrospective study analyzed 17 patients with chronic-phase chronic myeloid leukaemia, tracking how diagnostic approaches influenced risk stratification and treatment selection.

Bone Marrow Findings Did Not Change Initial Management

Twelve patients underwent both peripheral blood and bone marrow karyotyping within eight weeks of each other, while five were assessed using blood testing alone.

Bone marrow findings did not change initial management or risk classification in any of the paired cases, according to the study published in the Am J Hematol (Am J Hematol. 2026).

Blood Testing Alone Successfully Stratified Patient Risk

Patients assessed through peripheral blood testing alone were successfully risk-stratified using the EUTOS long-term survival score and started on imatinib without complications.

One year into treatment, four of those five patients achieved a major molecular response, and one achieved a complete cytogenetic response.

Study Limitations and Future Validation

Marrow evaluations remain useful if clinicians suspect disease progression, find blood cytogenetic results insufficient, or encounter unexplained cytopenias or other signs pointing to a secondary marrow condition.

Generalisability is constrained because the research is based on a limited patient cohort, used a retrospective approach, and was conducted at only one facility.

A larger cohort relying solely on blood tests might also overlook unusual abnormalities restricted to the marrow, such as substantial fibrosis or localized clusters of blasts.

To confirm these findings prospectively, the authors advocate for testing a structured blood-driven diagnostic algorithm that incorporates simultaneous marrow evaluations and independent assessments of treatment choices.